Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.05 USD
+0.05 (1.00%)
Updated May 29, 2024 03:59 PM ET
After-Market: $5.07 +0.02 (0.40%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 41 - 60 ( 221 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Highlights SY-1425''s Potential in Newly-Diagnosed, Unfit AML Patients
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Presentation Highlights SY-1425 Place in AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Webinar Highlights SY-1425''s Potential in Higher-Risk MDS
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update - Heme Franchise Progresses with 2021 Focus on SY-5609
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Milestones Within View for Syros to Accomplish; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update - Important Readouts to Keep an Eye on During 2021 & 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Expecting Progress from Pipeline in 2021 to Provide More Clarity; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASH Presentations Show SYRS Expanding its Footprint in Hematologic Disorders
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Promising Go-Forward Strategy for Heme Franchise Backed by $90.5M Raise
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z